Genfit reports the entry into Phase I trials of GFT505, the company’s molecule for the simultaneous treatment of several risk factors of cardiometabolic disease.

According to a Genfit spokesperson, GFT505, a multimodal, pluripotent compound, acts on the molecular level by activating PPAR (peroxisome proliferator-activated receptors) nuclear receptors, which play a central role in the regulation of lipid metabolism and the control of glycemia.

“With a completely original profile—Pan-sPPARm, selective PPAR modulator, with a preferential action on the PPAR alpha family—and evaluated by Genfit’s proprietary SNuRM technology platform, GFT505 targets a wide range of indications: mixed dyslipidemia, type II diabetes, and atherosclerosis,” explains Dean Hum, vp and CSO.

Previous articleSuccess Strategy for Bioinformatics Market Outlined
Next articlesanofi pasteur Completes First Clinical Trial Lot of Novel H7N1 Vaccine